ArticleCell biochemistry and biophysics2025
Synergistic Nanoformulation: Streamlined One-Pot Synthesis Enhances Paclitaxel Functionalization Gold Nanoparticles for Potent Anticancer Activity.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sustainable gold nanoparticles using Jania rubens, targeted therapeutic potential in prostate cancer and mechanistic insights via GO/KEGG pathway analysis.Scientific reports · 2026Article
- Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges.Cancers · 2025Review
- Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy.Frontiers in immunology · 2025Review
- Gold nanoparticles in the diagnosis and treatment of ovarian and cervical cancers: a comprehensive understanding.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of innovative, eco-friendly methods for synthesizing functional nanoparticles is crucial in advancing cancer therapeutics. This study highlights a one-pot in situ synthesis of paclitaxel-functionalized gold nanoparticles (PTX-AuNPs), with paclitaxel serving as both the reducing and stabilizing agent. The synthesis process was validated using UV-visible spectroscopy, X-ray diffraction (XRD), Fourier transform infrared (FTIR) spectroscopy, and high-resolution transmission electron microscopy (FEG-TEM). High-performance liquid chromatography (HPLC) confirmed the purity and structural integrity of paclitaxel before and after synthesis. The resulting PTX-AuNPs exhibited potent anticancer activity against human cervical cancer (SiHa) and human colon cancer (HT-29) cell lines, with a significantly stronger effect on the HT-29 cell line. A concentration-dependent reduction in HT-29 cell growth was observed as nanoparticle concentrations increased from 10 µg/mL-20 µg/mL. Molecular docking studies further demonstrated paclitaxel's strong binding affinity (-8.5 kcal/mol) to β-Tubulin, elucidating its anticancer mechanism. This cost-effective and environmentally friendly approach offers significant promise for enhancing cancer treatment strategies.
Indexed as
Identifiers
40011315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.